2 results
Approved WMOWill not start
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
Approved WMORecruiting
The objectives of this trial are:1. To define the performance characteristics of FDHT PET in patients with metastasized castrate resistant prostate cancer(mCRPC).(a) To demonstrate the kinetics of displacement of the tracer off of the androgen…